ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

VAL Valirx Plc

3.55
-0.30 (-7.79%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Valirx Plc LSE:VAL London Ordinary Share GB00BLH13C52 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.30 -7.79% 3.55 3.50 3.60 3.85 3.55 3.85 888,756 16:01:48
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Medical Laboratories 0 -2.37M -0.0262 -1.35 3.2M

ValiRx PLC Notice of GM (9238T)

06/07/2018 4:42pm

UK Regulatory


Valirx (LSE:VAL)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Valirx Charts.

TIDMVAL

RNS Number : 9238T

ValiRx PLC

06 July 2018

VALIRX PLC

("ValiRx", the "Company" or the "Group")

SHAREHOLDER CIRCULAR AND NOTICE OF GENERAL MEETING

London, UK. 6 July 2018: ValiRx Plc (AIM: VAL), a clinical stage biotechnology company, announces that it has today published and posted to shareholders a circular and notice convening a General Meeting of ValiRx Plc, to be held at the offices of DAC Beachcroft LLP at 100 Fetter Lane, London EC4A 1BN at 11:30 a.m. on 24 July 2018.

The directors will propose at the General Meeting shareholder resolutions seeking shareholder authority to allot shares and the dis-application of pre-emptive rights.

A copy of the Circular and this announcement will be available on the Company's website shortly: www.valirx.com.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

*** ENDS ***

For more information, please contact:

 
 
 ValiRx plc                                 Tel: +44 (0) 20 3008 4416 
                                             www.valirx.com 
 Dr Satu Vainikka, Chief Executive          Tel: +44 (0) 20 3008 4416 
 Tarquin Edwards, Head of Communications.   Tel: +44 (0) 7879 458 
                                             364 
                                             tarquin.edwards@valirx.com 
 Cairn Financial Advisers LLP (Nominated    Tel: +44 (0) 20 7213 0880 
  Adviser) 
  Liam Murray / Jo Turner 
 Novum Securities Limited                   Tel: +44 (0) 20 7399 9400 
  Colin Rowbury 
 

Notes for Editors

About ValiRx

ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.

The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.

ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights. They originate or derive from World class institutions, such as Cancer Research UK and Imperial College.

Until recently, cancer treatments relied on non-specific agents, such as chemotherapy. With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NOGFKADQPBKDDOK

(END) Dow Jones Newswires

July 06, 2018 11:42 ET (15:42 GMT)

1 Year Valirx Chart

1 Year Valirx Chart

1 Month Valirx Chart

1 Month Valirx Chart

Your Recent History

Delayed Upgrade Clock